Track Eli Lilly and Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Eli Lilly and Company LLYC.VI · Stock Open Eli Lilly and Company in new tab

706.40 EUR
P/E
131.06
EPS
5.39
Yield
0.65%
P/B
58.98
ROE
48.44
Beta
0.34
Loading chart...
Key Metrics
Earnings dateApril 30, 2024
P/E131.06
EPS5.39
Book Value11.98
Price to Book58.98
Debt/Equity243.63
% Insiders0.163%
Growth
Revenue Growth0.28%
Earnings Growth0.13%
Dividend
Dividend Yield0.65%
Annual dividends4.75 EUR
Ex-Div. DateFeb. 14, 2024
Payout77.93%

DCF Valuation

Tweak assumptions to recompute fair value for Eli Lilly and Company (LLYC.VI)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Eli Lilly and Company Logo Eli Lilly and Company Analysis (LLYC.VI)

United States Health Care Official Website Stock

Is Eli Lilly and Company a good investment? Eli Lilly and Company (LLYC.VI) is currently trading at 706.40 EUR.

In terms of valuation, the stock trades at a P/E ratio of 131.06. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Eli Lilly and Company is expected to release its next earnings report on April 30, 2024.

For income investors, Eli Lilly and Company pays a dividend yield of 0.65%. With a payout ratio of 78%, the dividend appears to be under pressure.

Investor FAQ

Does Eli Lilly and Company pay a dividend?

Yes, it pays an annual dividend of 4.75 EUR (0.65% yield).

What asset class is Eli Lilly and Company?

Eli Lilly and Company is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be April 30, 2024. The company currently has a trailing EPS of 5.39.

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Trades
Dividend Yield
0.65%
Annual Dividends
4.75EUR
Next Ex. Div Date
Feb. 14, 2024
Payout Ratio
77.93%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
2024
1.30 EUR
Feb. 14, 2024 1.3000
2023
4.52 EUR
Nov. 14, 2023 1.1300
Aug. 14, 2023 1.1300
May 12, 2023 1.1300
Feb. 14, 2023 1.1300
2022
3.92 EUR
Nov. 14, 2022 0.9800
Aug. 12, 2022 0.9800
May 13, 2022 0.9800
Feb. 14, 2022 0.9800
2021
3.40 EUR
Nov. 12, 2021 0.8500
Aug. 12, 2021 0.8500
May 13, 2021 0.8500
Feb. 11, 2021 0.8500
2020
2.96 EUR
Nov. 12, 2020 0.7400
Aug. 13, 2020 0.7400
May 14, 2020 0.7400
Feb. 13, 2020 0.7400
2019
0.65 EUR
Nov. 14, 2019 0.6450
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion